Dräger today announced the first implementations of its new Infinity® M300 patient-worn monitor. The new telemetry system has been installed at major hospitals in the United States and in Germany.
Infinity M300 provides the performance of a full-size patient monitor, packaged in a compact patient-worn telemetry device for adult and pediatric patients. This new design supports hospitals in their initiatives to mobilize patients as early as possible in order to accelerate the healing process.
In addition to monitoring ECG and SpO2, the device has built-in algorithms to enhance ECG processing and reduce false alarms – such as pacer detection software and ACE® (Arrhythmia Classification Expert), an arrhythmia analysis tool.
Infinity M300 can run on a hospital’s existing 802.11 b/g network – saving the expense of requiring a separate wireless network for the telemetry system. Infinity M300 addresses the three major challenges of telemetry monitoring. The first is viewing patient information at the patient’s side. Unlike traditional telemetry devices which have no screen, Infinity M300 has a color display that shows the patient’s ECG for all monitored leads, heart rate, SpO2, and electrode status – enabling the clinical staff to access monitored data and react promptly without having to go to the central monitoring station. The display also shows patient demographics to help confirm the patient’s identification before giving medication, taking blood samples, or performing treatments.
The second telemetry challenge is hearing and responding to alarms. Infinity M300 has built-in alarming and alarm controls, which provide alarm alerts both at the patient’s side and the Infinity CentralStation, Dräger’s central monitoring workstation. The built-in display helps the clinician assess alarms and respond accordingly.
The third challenge of telemetry monitoring is the cost and effort associated with disposable batteries. Infinity M300 has a built-in battery, which can be recharged via a bedside charger while the patient is wearing the device, or at a multi-device charger at the central monitoring station.
“Infinity M300 represents a major innovation in telemetry monitoring. We’re very excited about the system’s potential to help address the challenges of today’s busy ambulatory environments,” said Dina LaTulippe, Director of Product Management, Central Monitoring Solutions at Monitoring, Systems & IT in Andover, Massachusetts, USA. “Because Infinity M300 has a built-in display and alarms, it enables the clinical staff to be alerted to patient conditions without having to use additional devices.”
Founded in 1889, Drägerwerk AG & Co. KGaA is an international leader in the fields of medical and safety technology. Dräger products protect, support and save human life. In 2007, the Group achieved sales of €1,819.5 million worldwide and an EBIT of €151.9 million. Today, Dräger employs around 10,000 people in more than 70 subsidiaries worldwide and has representation in around 190 countries. The Dräger Medical subsidiary offers products, services and integrated system solutions which accompany the patient throughout the care process – Emergency Care, Perioperative Care, Critical Care or Perinatal care and Home Mechanical Ventilation.Contact for Trade Press
Burkard Dillig | Drägerwerk AG & Co. KGaA
'Virtual biopsy' allows doctors to accurately diagnose precancerous pancreatic cysts
06.12.2019 | Ohio State University Wexner Medical Center
Ultrasound techniques give warning signs of preterm births
05.12.2019 | Acoustical Society of America
University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making
In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...
With ultracold chemistry, researchers get a first look at exactly what happens during a chemical reaction
The coldest chemical reaction in the known universe took place in what appears to be a chaotic mess of lasers. The appearance deceives: Deep within that...
Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.
Fibroblasts kit - ready to heal wounds
Research from a leading international expert on the health of the Great Lakes suggests that the growing intensity and scale of pollution from plastics poses serious risks to human health and will continue to have profound consequences on the ecosystem.
In an article published this month in the Journal of Waste Resources and Recycling, Gail Krantzberg, a professor in the Booth School of Engineering Practice...
03.12.2019 | Event News
15.11.2019 | Event News
15.11.2019 | Event News
06.12.2019 | Earth Sciences
06.12.2019 | Life Sciences
06.12.2019 | Information Technology